Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence

Max, Blake; Sherer, Renslow
June 2000
Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS96
Academic Journal
Examines the therapeutic agents included in the highly active antiretroviral therapy (HAART) for the treatment of patients with HIV infections. Link between poor adherence and failure of antiretroviral therapy; Threat of short term-adverse effects to successful introduction and maintenance of HAART; Nucleoside reverse transcriptase inhibitors; Non-nucleoside reverse transcriptase inhibitors; Protease inhibitors.


Related Articles

  • HIV-1 Protease Inihibitors. Eron Jr., Joseph J. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS160 

    Focuses on the role of protease inhibitors (PI) in the antiretroviral therapy for HIV-1 infected patients. Potent activity in vitro of five United States Food and Drug Administration-approved PI agents; Suppression of HIV-1 replication by PI agents with two nucleoside analogue reverse...

  • New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review. Lee, Elmer C.C.; Walmsley, Sharon; Fantus, I. George // CMAJ: Canadian Medical Association Journal;7/27/99, Vol. 161 Issue 2, p161 

    Presents a case of new-onset diabetes mellitus associated with protease inhibitor therapy in a 56-year-old HIV-positive man. Medical history, including his CD4 count and his parents' type of diabetes; Dosage of oral hypoglycemic agents; Antiretroviral therapy; Possible mechanism by which...

  • HIV clinical trials are not enough. Millson, Margaret E.; Rachlis, Anita R. // CMAJ: Canadian Medical Association Journal;3/09/99, Vol. 160 Issue 5, p669 

    Editorial. Discusses antiretroviral drug regimens for HIV infection. The paradigm of HIV therapy being complete suppression of viral replication to preserve and restore immune function and to delay or prevent the emergence of drug resistance; Reference to a study by Robert S. Hogg and...

  • Compliance and dosage critical in HIV suppression by protease inhibition.  // AIDS Patient Care & STDs;Dec96, Vol. 10 Issue 6, p377 

    Reports that starting and maintaining protease inhibitor therapy at the recommended dosages delays the development of resistant HIV virus and assists in long-term viral suppression. Presentation of indinavir (Crixivan) data.

  • Editorial Response: Discordance between Virological, Immunologic, and Clinical Outcomes of Therapy with Protease Inhibitors among Human Immunodeficiency Virus-Infected Patients. Goetz, Matthew Bidwell // Clinical Infectious Diseases;12/1/1999, Vol. 29 Issue 6, p1431 

    Comments on the findings of I. Mezzaroma, M. Carlesimo, E. Pinter et al on the occurrence of discordant virological and immunologic responses among HIV-infected patients who had received protease inhibitor-based antiretroviral therapy, published in the December 1999 issue of the journal...

  • Ritonavir for advanced HIV infection.  // American Family Physician;7/1/1996, Vol. 54 Issue 1, p372 

    Reports that the United States Food and Drug Administration has approved the protease inhibitor ritonavir for the treatment of patients with human immunodeficiency virus (HIV) infection. Combination of ritonavir with nucleoside analogs or as monotherapy; Clinical trials on the efficacy of...

  • HIV Protease Inhibitor--Related Lipodystrophy Syndrome. Carr, Andrew // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS135 

    Explores the association of HIV protease inhibitor (PI) therapy with lipodystrophy syndrome. Occurrence of peripheral lipoatrophy during the course of the therapy; Asymptomatic and nonketotic clinical presentation in diabetes associated with PI therapy; Abnormal lipodystrophy and metabolic...

  • Determinants of Virological Response to Antiretroviral Therapy: Implications for Long-Term... Deeks, Steven G. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS177 

    Discusses the determinants of virological failure in protease inhibitor-including regimen for treatment of HIV infections. Potency of existing regimens; Baseline CD4[sup +] T cell count and viral load; Pre-existing viral resistance; Medication adherence; Pharmacokinetics; Role of viral...

  • Introduction. Murphy, Robert L. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS95 

    Discusses the challenges faced by clinicians in choosing an effective treatment regimen for patients with HIV infections. Decrease in the success rate and sustained treatment response to second-line therapies in clinics; Need to find effective treatment options that have favorable...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics